Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
European Commission to make final decision on arimoclomol MAA following negative CHMP opinion European Commission to make final decision on arimoclomol MAA following negative CHMP opinion
Covered in this story
Call it yourself
No calls on $MAA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Mid-America Apartment Communities →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.